Maxcyte (MXCT) Operating Income (2020 - 2025)
Historic Operating Income for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to -$14.1 million.
- Maxcyte's Operating Income fell 68.31% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.6 million, marking a year-over-year decrease of 1547.68%. This contributed to the annual value of -$51.2 million for FY2024, which is 600.01% down from last year.
- According to the latest figures from Q3 2025, Maxcyte's Operating Income is -$14.1 million, which was down 68.31% from -$14.2 million recorded in Q2 2025.
- Maxcyte's 5-year Operating Income high stood at -$2.4 million for Q3 2021, and its period low was -$14.2 million during Q2 2025.
- Moreover, its 5-year median value for Operating Income was -$12.0 million (2024), whereas its average is -$9.8 million.
- Its Operating Income has fluctuated over the past 5 years, first soared by 3473.98% in 2022, then crashed by 21684.74% in 2023.
- Maxcyte's Operating Income (Quarter) stood at -$5.0 million in 2021, then plummeted by 36.23% to -$6.8 million in 2022, then fell by 19.93% to -$8.1 million in 2023, then plummeted by 59.35% to -$12.9 million in 2024, then fell by 9.67% to -$14.1 million in 2025.
- Its Operating Income was -$14.1 million in Q3 2025, compared to -$14.2 million in Q2 2025 and -$12.3 million in Q1 2025.